Published in J Thromb Haemost on December 21, 2009
Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med (2010) 3.32
Hemorrhagic complications after prasugrel (Effient) therapy for vascular neurointerventional procedures. J Neurointerv Surg (2012) 1.28
Implementing genotype-guided antithrombotic therapy. Future Cardiol (2010) 0.85
Association of MicroRNAs and YRNAs With Platelet Function. Circ Res (2015) 0.84
Clinical, pharmacokinetic, and pharmacogenetic determinants of clopidogrel resistance in Korean patients with acute coronary syndrome. Korean J Lab Med (2011) 0.82
P2Y12 Receptor Inhibitors in Acute Coronary Syndromes: What Is New on the Horizon? Cardiol Res Pract (2013) 0.79
Influence of CYP2C19 loss-of-function variants on the antiplatelet effects and cardiovascular events in clopidogrel-treated Chinese patients undergoing percutaneous coronary intervention. Eur J Clin Pharmacol (2012) 0.77
Comparison of a new P2Y12 receptor specific platelet aggregation test with other laboratory methods in stroke patients on clopidogrel monotherapy. PLoS One (2013) 0.76
Evaluation of CYP2C19, P2Y12, and ABCB1 polymorphisms and phenotypic response to clopidogrel in healthy Indian adults. Indian J Pharmacol (2016) 0.75
Increased platelet reactivity is associated with circulating platelet-monocyte complexes and macrophages in human atherosclerotic plaques. PLoS One (2014) 0.75
Is ticagrelor the antiplatelet therapy panacea? Circ Cardiovasc Genet (2010) 0.75
Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med (1990) 2.82
Immediate versus deferred coronary angioplasty in non-ST-segment elevation acute coronary syndromes. Heart (2008) 2.40
Procoagulant and proinflammatory activity in acute coronary syndromes. Cardiovasc Res (1998) 2.12
Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA (1993) 1.88
Platelet- and erythrocyte-derived microparticles trigger thrombin generation via factor XIIa. J Thromb Haemost (2012) 1.86
Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med (1994) 1.64
The impact of blood coagulability on atherosclerosis and cardiovascular disease. J Thromb Haemost (2012) 1.63
Regulation of interleukin 10 release by tumor necrosis factor in humans and chimpanzees. J Exp Med (1994) 1.63
Review: infectious diseases and coagulation disorders. J Infect Dis (1999) 1.50
Pravastatin reduces fibrinogen receptor gpIIIa on platelet-derived microparticles in patients with type 2 diabetes. J Thromb Haemost (2005) 1.50
Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest (1994) 1.50
A case-control study on platelet reactivity in patients with coronary stent thrombosis. J Thromb Haemost (2011) 1.43
Clinical, biochemical and genetical resistance to clopidogrel in a patient with recurrent stent thrombosis. Int J Cardiol (2006) 1.39
Spontaneous bile flow in the pancreatic duct. Endoscopy (2004) 1.39
ADAMTS-13, von Willebrand factor and related parameters in severe sepsis and septic shock. J Thromb Haemost (2007) 1.32
Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees. Blood (1994) 1.28
Giant aneurysm of an aortocoronary venous bypass graft compressing the right ventricle. Neth Heart J (2007) 1.28
Is chronic HIV infection associated with venous thrombotic disease? A systematic review. Neth J Med (2005) 1.27
Sickle cell disease; a general overview. Neth J Med (2004) 1.26
Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor. J Clin Invest (1998) 1.21
The in vivo kinetics of tissue factor messenger RNA expression during human endotoxemia: relationship with activation of coagulation. Blood (2000) 1.18
The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia. Eur J Clin Invest (1997) 1.17
Images in focus. An accessory gallbladder (double gallbladder) with an accessory cystic duct. Endoscopy (2000) 1.16
Detection of factor X activation in humans. Blood (1989) 1.15
Factor IX is activated in vivo by the tissue factor mechanism. Blood (1990) 1.13
Is clinical outcome of dengue-virus infections influenced by coagulation and fibrinolysis? A critical review of the evidence. Lancet Infect Dis (2003) 1.13
Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: major role for C1-inhibitor. Blood (1995) 1.12
Disseminated intravascular coagulation. Thromb Haemost (1999) 1.12
Effect of gender difference on platelet reactivity. Neth Heart J (2011) 1.09
Activation of clotting factors XI and IX in patients with acute myocardial infarction. Arterioscler Thromb Vasc Biol (2000) 1.08
From neutrophil extracellular traps release to thrombosis: an overshooting host-defense mechanism? J Thromb Haemost (2011) 1.06
Release of soluble receptors for tumor necrosis factor in clinical sepsis and experimental endotoxemia. J Infect Dis (1993) 1.05
Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans. Blood (1989) 1.03
Acute and subacute stent thrombosis after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: incidence, predictors and clinical outcome. J Thromb Haemost (2010) 1.01
Preanalytic variables of thrombin generation: towards a standard procedure and validation of the method. J Thromb Haemost (2012) 1.01
Increased PAI-1 plasma levels and risk of death from dengue: no association with the 4G/5G promoter polymorphism. Thromb J (2005) 1.00
Endoscopic treatment of pancreatic fistulas. Surg Endosc (2006) 0.99
Preferential upregulation of interferon-alpha subtype 2 expression in HIV-1 patients. AIDS Res Hum Retroviruses (2009) 0.98
Modulation of contact system proteases by glycosaminoglycans. Selective enhancement of the inhibition of factor XIa. J Biol Chem (1996) 0.97
Effect of hormonal manipulation on antithrombin III activity in patients with prostatic carcinoma. Eur Urol (1984) 0.97
A head-to-head comparison between the VerifyNow P2Y12 assay and light transmittance aggregometry for monitoring the individual platelet response to clopidogrel in patients undergoing elective percutaneous coronary intervention. J Thromb Haemost (2006) 0.97
Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemost (1992) 0.96
Effectiveness of endoscopic treatment modalities in complicated hepatic hydatid disease after surgical intervention. Endoscopy (2001) 0.96
Genitourinary brucellosis: results of a multicentric study. Clin Microbiol Infect (2014) 0.96
Advances in the understanding of the pathogenetic pathways of disseminated intravascular coagulation result in more insight in the clinical picture and better management strategies. Semin Thromb Hemost (2001) 0.95
Protein C and S and inflammation in sickle cell disease. Am J Hematol (2004) 0.95
Pentoxifylline attenuates neutrophil activation in experimental endotoxemia in chimpanzees. J Immunol (1993) 0.95
Active site inhibited factor VIIa attenuates myocardial ischemia/reperfusion injury in mice. J Thromb Haemost (2008) 0.94
Liver involvement in patients with brucellosis: results of the Marmara study. Eur J Clin Microbiol Infect Dis (2014) 0.93
The 20210 G-->A mutation in the 3'-untranslated region of the prothrombin gene and the risk for arterial thrombotic disease. Br J Haematol (1999) 0.92
Low-intensity oral anticoagulation in sickle-cell disease reverses the prethrombotic state: promises for treatment? Br J Haematol (1995) 0.92
Long term follow up after elective percutaneous coronary intervention for unprotected non-bifurcational left main stenosis: is it time to change the guidelines? Heart (2003) 0.91
Novel approaches to the management of disseminated intravascular coagulation. Crit Care Med (2000) 0.91
Unusual complications after embolization of a pulmonary arteriovenous malformation. Chest (1996) 0.91
The plasma kallikrein-kinin system and risk of cardiovascular disease in men. J Thromb Haemost (2007) 0.91
Complete inhibition of endotoxin-induced coagulation activation in chimpanzees with a monoclonal Fab fragment against factor VII/VIIa. Thromb Haemost (1995) 0.90
Effects of a 3-month course of rosuvastatin in patients with systemic lupus erythematosus. Ann Rheum Dis (2009) 0.90
The use of the VerifyNow system to monitor antiplatelet therapy: a review of the current evidence. Platelets (2008) 0.90
Activation of coagulation factor XI, without detectable contact activation in dengue haemorrhagic fever. Br J Haematol (2001) 0.90
Tumor necrosis factor is involved in the appearance of interleukin-1 receptor antagonist in endotoxemia. J Infect Dis (1994) 0.89
Thrombin generation in patients with a first acute myocardial infarction. J Thromb Haemost (2011) 0.89
Soluble tissue factor is a candidate marker for progression of microvascular disease in patients with Type 2 diabetes. J Thromb Haemost (2005) 0.89
Activation of the intrinsic pathway of coagulation in children with meningococcal septic shock. Thromb Haemost (1995) 0.88
Erythropoiesis and serum sVCAM-1 levels in adults with sickle cell disease. Ann Hematol (2003) 0.88
Delivery of Chlamydia pneumoniae to the vessel wall aggravates atherosclerosis in LDLr-/- mice. Cardiovasc Res (2005) 0.88
Endoscopic treatment of a large upper gastrointestinal anastomotic leak using a prolene plug and cyanoacrylate. Endoscopy (2005) 0.87
Is platelet inhibition due to thienopyridines increased in elderly patients, in patients with previous stroke and patients with low body weight as a possible explanation of an increased bleeding risk? Neth Heart J (2011) 0.87
Clopidogrel resistance caused by a failure to metabolize clopidogrel into its metabolites. J Thromb Haemost (2006) 0.86
Inhibition of the release of soluble tumor necrosis factor receptors in experimental endotoxemia by an anti-tumor necrosis factor-alpha antibody. J Clin Immunol (1995) 0.85
Combined influence of proton-pump inhibitors, calcium-channel blockers and CYP2C19*2 on on-treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention. J Thromb Haemost (2011) 0.85
Platelet-activating factor antagonist TCV-309 attenuates the induction of the cytokine network in experimental endotoxemia in chimpanzees. J Immunol (1994) 0.85
Comparative investigation of a quantitative chromogenic endotoxin assay and blood cultures. Am J Clin Pathol (1984) 0.84
Biological variation in inflammatory and hemostatic markers. J Thromb Haemost (2009) 0.84
Cytokines: triggers of clinical thrombotic disease. Thromb Haemost (1997) 0.84
Prognostic significance of incident atrial fibrillation following STEMI depends on the timing of atrial fibrillation. Neth Heart J (2015) 0.84
Functional role of the 503F variant of the organic cation transporter OCTN1 in Crohn's disease. Gut (2005) 0.84
Patent foramen ovale causing position-dependent shunting in a patient, when laying down her corset. Eur Respir J (2001) 0.84
Automated amidolytic method for determining heparin, a heparinoid, and a low-Mr heparin fragment, based on their anti-Xa activity. Clin Chem (1984) 0.84
High on-aspirin platelet reactivity as measured with aggregation-based, cyclooxygenase-1 inhibition sensitive platelet function tests is associated with the occurrence of atherothrombotic events. J Thromb Haemost (2010) 0.83
Homocysteine and markers of coagulation and endothelial cell activation. J Thromb Haemost (2004) 0.83
Prevalence of hereditary haemochromatosis in premature atherosclerotic vascular disease. Br J Haematol (1998) 0.83
The microbiological diagnosis of tuberculous meningitis: results of Haydarpasa-1 study. Clin Microbiol Infect (2014) 0.83